HoFH, the International Clinical Collaborators Registry

Launched by UNIVERSITY OF PENNSYLVANIA · Mar 23, 2021

Keywords

ClinConnect Summary

This clinical trial, called the HoFH International Clinical Collaborators Registry, is focused on a rare genetic condition known as homozygous familial hypercholesterolemia (HoFH). This condition leads to very high cholesterol levels from birth and can cause heart problems at an early age. The goal of the study is to gather information from patients diagnosed with HoFH to better understand this disease and improve future treatments. Researchers from around the world are collecting data on patients to help create a clearer picture of how HoFH affects individuals.

To participate in this study, individuals must have a confirmed diagnosis of HoFH, either through clinical assessment or genetic testing. There are no restrictions based on age or gender, as all individuals with HoFH may be eligible. Participants can expect to contribute valuable information that may help advance research on this condition. It’s important to note that this study is currently recruiting participants, so there’s an opportunity for those affected by HoFH to play a role in improving knowledge and treatment options for this rare disorder.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined
• Exclusion Criteria:
• • No diagnosis of HoFH